Hatice Terzi1 
,
Merve Ergül2
For correspondence:- Hatice Terzi Email: dr.terzi@hotmail.com Tel:+905052966986
Accepted: 18 October 2020 Published: 30 November 2020
Citation: Terzi H, Ergül M. Evaluation of potential cytotoxic and apoptotic effects of bioymifi on human multiple myeloma cell lines. Trop J Pharm Res 2020; 19(11):2363-2367 doi: 10.4314/tjpr.v19i11.17
© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the cytotoxic and apoptotic activities of bioymifi (DR5 agonist) on bortezomib-sensitive and bortezomib-resistant cells.
Methods: The cytotoxic activities of bioymifi against bortezomib-sensitive (U266) and bortezomib-resistant (U266/BR) cells were evaluated using XTT cell viability test. The cells were exposed to increasing concentrations of bioymifi for 24 h. Cell cycle analysis was performed while apoptosis was examined by flow cytometry.
Results: Bioymifi showed significant cytotoxic effects on U266 and U266/BR in a concentration-dependent manner (p < 0.05). The IC50 values of bioymifi in U266 and U266/BR cells were 10.4 and 20.9 µM, respectively. Moreover, when compared to the untreated cells, bioymifi treatment at IC50 concentrations considerably increased the percentage of apoptotic cells. Bioymifi treatment also caused cell cycle arrest at the G2/M phase in both cell types.
Conclusion: The results show that bioymifi is a promising candidate for multiple myeloma treatment. However, further studies are required to evaluate the clinical anticancer activity of this agent.
Archives
News Updates
Fulltext in PDF